---
title: "Akeso Trustee Purchases Approximately 200,000 Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306120245.md"
description: "Akeso, Inc. ( (HK:9926) ) has shared an update.Akeso, Inc., incorporated in the Cayman Islands and operating with subsidiaries, announced that its trustee purchased approximately 200,000 company shares on the market on November 19, 2026, for aggregate consideration of approximately HK$12 million. The purchase was funded by the Company’s existing available cash resources."
datetime: "2026-11-19T12:38:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306120245.md)
  - [en](https://longbridge.com/en/news/306120245.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306120245.md)
generator: "portal-rs"
---

# Akeso Trustee Purchases Approximately 200,000 Shares

Akeso, Inc. ( (HK:9926) ) has shared an update.

Akeso, Inc., incorporated in the Cayman Islands and operating with subsidiaries, announced that its trustee purchased approximately 200,000 company shares on the market on November 19, 2026, for aggregate consideration of approximately HK$12 million. The purchase was funded by the Company’s existing available cash resources.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**